论文部分内容阅读
线粒体12S核糖体核糖核酸(Ribosomal Ribonucleic Acid,rRNA)基因突变是发生耳聋的重要遗传因素之一,携带线粒体12S rRNA突变基因的人对氨基糖甙类抗生素(Aminoglycosides Antibiotic,Am An)高度敏感,接触Am An可导致不可逆性的听力损伤。近年来,一些地区将基因筛查引入新生儿体检,从而及时发现线粒体12S rRNA基因突变儿童,采取针对性指导,避免临床用药中使用Am An,减少药物性耳聋的发生。儿童接种用疫苗由于工艺要求存在痕量抗生素的残留,但目前尚无针对12S rRNA基因突变儿童接种疫苗的指导意见。现从线粒体12S rRNA基因突变与Am An致聋机制、疫苗中抗生素应用现状及接种疫苗后耳聋报告等方面综述,探究线粒体12S rRNA基因突变儿童接种疫苗致聋的安全性。
Mitochondrial 12S ribosomal ribosomal RNA (Ribosomal Ribonucleic Acid, rRNA) gene mutation is one of the important genetic factors of deafness. People who carry mitochondrial 12S rRNA mutation gene are highly sensitive to Aminoglycosides Antibiotic (Am An) Am An can cause irreversible hearing loss. In recent years, some regions have introduced genetic screening into neonatal examination to detect mitochondrial 12S rRNA gene mutation in time and take targeted guidance to avoid the use of Am An in clinical medication to reduce the occurrence of drug-induced deafness. There are no guidelines for vaccination of children with 12S rRNA mutations because of the presence of traces of antibiotic residues in vaccines for children. The mitochondrial 12S rRNA gene mutation and Am An mechanism of deafness, the application of antibiotics in vaccines and deafness report after vaccination were reviewed to explore the safety of deafness in children with mitochondrial 12S rRNA gene mutation vaccination.